Advertisement
Canada markets close in 4 hours 49 minutes
  • S&P/TSX

    22,175.64
    +68.56 (+0.31%)
     
  • S&P 500

    5,251.07
    +2.58 (+0.05%)
     
  • DOW

    39,723.89
    -36.19 (-0.09%)
     
  • CAD/USD

    0.7378
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    82.72
    +1.37 (+1.68%)
     
  • Bitcoin CAD

    96,561.16
    +1,995.72 (+2.11%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,234.40
    +21.70 (+0.98%)
     
  • RUSSELL 2000

    2,130.27
    +15.92 (+0.75%)
     
  • 10-Yr Bond

    4.1940
    -0.0020 (-0.05%)
     
  • NASDAQ

    16,391.86
    -7.66 (-0.05%)
     
  • VOLATILITY

    13.01
    +0.23 (+1.80%)
     
  • FTSE

    7,972.38
    +40.40 (+0.51%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6832
    +0.0027 (+0.40%)
     

SPPI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 1, 2021 in the Class Action Filed on Behalf of Spectrum Pharmaceuticals, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - October 19, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) alleging that the Company violated federal securities laws.

Class Period: December 27, 2018 and August 5, 2021
Lead Plaintiff Deadline: November 1, 2021
No obligation or cost to you.

Learn more about your recoverable losses in SPPI:
https://www.kleinstocklaw.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?id=20532&from=5

Spectrum Pharmaceuticals, Inc. NEWS - SPPI NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Spectrum Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

ADVERTISEMENT

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Spectrum you have until November 1, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Spectrum securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the SPPI lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100170